2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate

BACKGROUND: The respiratory syncytial virus (RSV) fusion glycoprotein (F) is a molecule that fuses the viral and host cell membranes during virus entry as it rearranges from a meta-stable prefusion to a stable postfusion conformation. Using structure-guided design, Pfizer engineered a prefusion RSV...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmoele-Thoma, Beate, Falsey, Ann R, Walsh, Edward E, Swanson, Kena, Zareba, Agnieszka, Cooper, David, Gruber, William C, Jansen, Kathrin U, Radley, David, Scott, Daniel, Dormitzer, Philip R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809502/
http://dx.doi.org/10.1093/ofid/ofz360.2432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809502/
http://dx.doi.org/10.1093/ofid/ofz360.2432

Ejemplares similares